The Worldwide KRAS InhibitorsKRAS Inhibitors Industry is Expected to Reach $4 Billion by 2029

09 Feb 2023
www.prnewswire.com
Drug ApprovalPhase 1
DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Global KRAS InhibitorsKRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to
ResearchAndMarkets.com's offering.
Report Highlights
Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029
Global KRAS Drug Market Growth In 2022 > 200%
Number Of Approved Drugs: 2 Drugs
Approved Drug Global & Regional Sales Insight
Approved Drugs Patent, Price & Dosage Analysis
Regional Analysis: USA, UK, China Europe, Japan, South Korea
Number Of Drugs In Clinical Trials: > 60 Drugs
Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment
The advancement in the field of biology has led to the discovery of several oncogenes that play a critical role in cancer development and thus presenting researchers with opportunities to target them. KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitorsKRAS inhibitors. The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.
Researchers worldwide have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable. But after the approval of first-ever KRAS inhibitorKRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for the treatment of patients with advanced KRAS G12C mutated non-small cell lung canceradvanced KRAS G12C mutated non-small cell lung cancer, the product market showed significant growth in terms of both commercial sale success and enhanced overall survival rates. Its sales grew more than twice in 2022 as compared to 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations.
Furthermore, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received US regulatory approval as a companion diagnostic in aiding the diagnosis of non-small cell lung cancer. This was the first companion diagnostic kit to have received premarket approval from the US FDA. Nevertheless, additional progress has been made in the industry and FDA has further approved companion diagnosis kits. In December 2022 Agilent Resolution's ctDx FIRST was granted approval by the FDA as a companion diagnostic for patients with NSCLC.
The ever-increasing cases of cancer and the ability of the tumor to develop new and frequent mutations signify an unmet need for advancement of novel therapies in the management and treatment of cancer. However, with discoveries like that of Kristen rat sarcoma viral oncogene homolog (KRAS), the future of cancer-targeted therapies is something to look forward to. It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.
With booming research and development strategies, pharmaceutical companies are rapidly moving forward and aiming for this oncogene. Recently, VITRAC Therapeutic has initiated a phase I clinical trial with AURKA Inhibitor VIC-1911 and Sotorasib a G12C inhibitor for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC)KRAS G12C-mutant non-small cell lung cancer (NSCLC). This study of VIC-1911 as monotherapy and in combination with Sotorasib is being performed at Yale Cancer Centre. The preclinical studies have strongly supported the combinational use of both drugs. By using this multi-targeted approach, the study aims to provide a more effective therapeutic outcome for patients with KRAS G12C-mutated NSCLC.
The market for KRAS-targeted drugs is poised with exponential growth with several factors determining its potential. The KRAS market is widely supported by the accelerating trend of preclinical and in vitro studies which has increased the number of patients that are seeking out treatment opportunities. The rising demand for this therapy has resulted in increasing acceptance of cancer management treatments. The market expects new medications to swiftly and rapidly enter the commercial sector.
There are also factors that will be challenging the future potential of this market. With increased research and development activity, there also increases in the number of competitors in the market. Drug manufacturers need to develop medications that have innovation and creativity and the ability to show better outcomes than its opponents. Currently, Amgen is in the lead for KRAS targeted therapy market but with the incoming of more drugs in the future, some challenges are bound to be faced by the company if it wants to keep its position as the topmost stakeholder in the KRAS inhibitorsKRAS inhibitors drug market.
For instance, on December 2022, the US FDA granted accelerated approval to Mirati Therapeutics' Adagrasib (Krazati) which is a RAS GTPase family inhibitorRAS GTPase family inhibitor for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancerKRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval was based on KRYSTAL-1, a multicenter, open-label clinical trial and the indication was approved under accelerated approval based on the overall response rate and duration of response.
Key Topics Covered:
1. Introduction to KRAS InhibitorsKRAS Inhibitors
2. Role of KRAS InhibitorsKRAS Inhibitors in Cancer Therapy
2.4 Other Cancers
3. Lumakras - First Approved KRAS InhibitorKRAS Inhibitor
3.1 Overview & Patent Insight
3.2 Dosage & Price Analysis
3.3 Sales Analysis
4. Krazati - Second Approved KRAS InhibitorKRAS Inhibitor
4.1 Overview & Patent Insight
4.2 Dosage & Price Analysis
5. Global KRAS InhibitorKRAS Inhibitor Market Outlook
5.1 Current Market Scenario
5.2 Future Market Opportunity
6. KRAS InhibitorKRAS Inhibitor Market Regional Analysis
6.1 US
6.2 UK
6.3 China
6.4 Europe
6.5 Japan
6.6 South Korea
6.7 Canada
7. Global KRAS Inhibitors Clinical Pipeline Overview
7.1 By Country
7.2 By Phase
7.3 By Company
7.4 By Indication
7.5 By Patient Segment
8. Global KRAS InhibitorsKRAS Inhibitors Clinical Pipeline By Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
9. Marketed KRAS InhibitorsKRAS Inhibitors Clinical Insight
9.1 Sotorasib - Amgen
10. Global KRAS InhibitorsKRAS Inhibitors Market Dynamics
10.1 Market Drivers & Opportunities for KRAS InhibitorsKRAS Inhibitors
10.2 Challenges for KRAS InhibitorsKRAS Inhibitors Market
11. Competitive Landscape
11.2 Applied Pharmaceutical Science
11.3 Amgen
11.9 Erasca
11.11 FogPharma
11.12 Frontier Medicines
11.14 Jemincare
11.19 REVOLUTION Medicines
11.20 Roche
For more information about this report visit https://www.researchandmarkets.com/r/7okz91-kras?w=5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact: Laura Wood | +353-1-481-1716 | [email protected]
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.